Open-Label Extension Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03714373|
Recruitment Status : Recruiting
First Posted : October 22, 2018
Last Update Posted : December 19, 2019
|Condition or disease||Intervention/treatment||Phase|
|Prader-Willi Syndrome||Drug: DCCR||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||105 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients With Prader-Willi Syndrome|
|Actual Study Start Date :||October 1, 2018|
|Estimated Primary Completion Date :||April 2021|
|Estimated Study Completion Date :||June 2023|
75 - 450 mg DCCR
Once daily oral administration
- Assess the safety of DCCR by evaluating the incidence and severity of adverse events reported [ Time Frame: Baseline to Week 54 or until resolution of certain adverse events at the discretion of the Investigator and Sponsor ]Safety analyses will be conducted in all subjects who receive at least one dose of DCCR. Adverse events will be described by type and level of severity.
- Hyperphagia Score [ Time Frame: Baseline to Week 52 ]Hyperphagia-related behaviors will be assessed by the hyperphagia questionnaire for clinical trials (HQ-CT), an instrument designed to measure symptoms of food related preoccupations and behaviors. The HQ-CT consists of nine items with responses ranging from 0-4 (best to worst). Scores from 9 items will be summed for a possible total score range of 0−36.
- Body fat mass (DXA) [ Time Frame: Baseline at Week 52 ]Change in Body Fat Mass from Baseline to Week 52
- Clinical Global Impression of Improvement (CGI-I) [ Time Frame: at Week 52 ]CGI-I is a single statement designed to assess the Investigator's overall perception of change in the subject's condition across the course of the clinical trial. The Investigator provides a response to "Compared to the subject's condition at enrollment, the subject's condition is:" by rating the subject's behavior using a 7-point response scale (best to worst).
- Caregiver Global Impression of Change (Caregiver GI-C) [ Time Frame: at Week 52 ]The Caregiver GI-C is a single statement designed to assess the caregiver's overall perception of change in the subject across the course of the clinical trial. The caregiver provides a response to "Please choose the response below that best describes the overall change in the person's PWS since they started taking the study medication" using a 7-point graded response scale (best to worst).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03714373
|Contact: C602 Project Manager||650-353-2051||C602ProjectManager@soleno.life|